Coreline Soft Receives U.S. FDA 510(k) Clearance for AVIEW Aorta Metrics, Expanding Its Chest CT AI Portfolio in the U.S.

October 23, 2026
7:52 am

SEOUL, South Korea and CHICAGO, Oct. 23, 2026 /PRNewswire/ -- Coreline Soft has received U.S. Food and Drug Administration (FDA) 510(k) clearance for AVIEW Aorta Metrics, its AI-powered aortic quantitative analysis software. The clearance, received on October 16, brings the company's total to 13 FDA 510(k) clearances.

AVIEW Aorta Metrics is a software medical device designed to automatically segment the aorta from chest CT images and provide quantitative diameter measurements across anatomical regions. The software automatically classifies aortic zones and measures the diameter of each zone, supporting consistent quantitative evaluation. It also provides straightened CPR (curved planar reformation), cross-sectional and 3D views, and analysis reports.

The latest FDA clearance aligns with Coreline Soft’s multi-disease analysis strategy based on chest CT imaging in the U.S. market.

Coreline Soft Receives U.S. FDA 510(k) Clearance for AVIEW Aorta Metrics, Expanding Its Chest CT AI Portfolio in the U.S.

Sign up for Blog Updates